DNA copy number analysis was performed using an oligonucleotide a-CGH platform (SurePrint G3 Human CGH Microarray 8x60K; Agilent Technologies Inc., Santa Clara, CA, USA), using a previously established protocol for FFPE samples [43 (link), 44 (link)]. DNA was isolated using the standard phenol-chloroform method. Reference DNA was prepared from the peripheral blood of a pool of ten healthy donors [45 (link)]. Equal amounts of tumor and reference genomic DNA (1–2 μg) were digested, enzymatically labeled using the SureTag Complete DNA Labeling Kit (Agilent Technologies, Inc., Santa Clara, CA, USA), and hybridized to the arrays. The array data were analyzed with the Feature Extraction v.10.10 software and Agilent CytoGenomics v.3.0 software (Agilent Technologies Inc., Santa Clara, CA, USA) using the ADM-2 algorithm, threshold 6.0, and an aberration filter with a minimum of >3 probes [45 (link)]. Copy number gains and losses were defined as previously described [44 (link)].
Free full text: Click here